

# FACT SHEET FOR HEALTHCARE PROVIDERS

Sofia 2 SARS Antigen FIA – Quidel Corporation

May 8, 2020

Coronavirus  
Disease 2019  
(COVID-19)

This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the Sofia 2 SARS Antigen FIA test.

The Sofia 2 SARS Antigen FIA test is authorized for use on respiratory specimens collected from individuals who are suspected of COVID-19 by their healthcare provider.

---

**All patients whose specimens are tested with this assay will receive the Fact Sheet for Patients: Sofia 2 SARS Antigen FIA.**

---

## What are the symptoms of COVID-19?

Many patients with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, dyspnea). The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that symptoms include cough, shortness of breath or dyspnea, fever, chills, myalgias, headache, sore throat or new loss of taste or smell. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 5 days, but may range 2-14 days.

Public health officials have identified cases of COVID-19 infection throughout the world, including the United States, which may pose risks for public health. Please check the CDC webpage for the most up to date information.

## What do I need to know about COVID-19 testing?

Current information on COVID-19 for healthcare providers is available at CDC's webpage, *Information for Healthcare Professionals* (see links provided in "Where can I go for updates and more information" section).

- The Sofia 2 SARS Antigen FIA can be used to test nasopharyngeal (NP) and nasal (NS) swab specimens directly or after the swabs have been added to viral transport media.

---

**This test is to be performed only using respiratory specimens collected from individuals who are suspected of COVID-19 by their healthcare provider.**

---

- The Sofia 2 SARS Antigen FIA should be ordered for the detection of COVID-19 in individuals who are suspected of COVID-19 by their healthcare provider.
- The Sofia 2 SARS Antigen FIA is only authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Specimens should be collected with appropriate infection control precautions. Current guidance for COVID-19 infection control precautions are available at the CDC's website (see links provided in "Where can I go for updates and more information" section).

Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of having COVID-19 as outlined in the CDC *Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)*. For additional information, refer to CDC *Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19)* (see links provided in "Where can I go for updates and more information" section).

## What does it mean if the specimen tests positive for the virus that causes COVID-19?

A positive test result for COVID-19 indicates that antigens from SARS-CoV-2 were detected, and the patient is infected with the virus and presumed to be contagious. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and

---

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**

# FACT SHEET FOR HEALTHCARE PROVIDERS

Sofia 2 SARS Antigen FIA – Quidel Corporation

May 8, 2020

Coronavirus  
Disease 2019  
(COVID-19)

patient management decisions. Patient management should follow current CDC guidelines.

The Sofia 2 SARS Antigen FIA has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 patients, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.

All laboratories using this test must follow the standard testing and reporting guidelines according to their appropriate public health authorities.

## What does it mean if the specimen tests negative for the virus that causes COVID-19?

A negative test result for this test means that antigens from SARS-CoV-2 were not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Antigen tests are known to be less sensitive than molecular tests that detect viral nucleic acids. Therefore, negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation indicate that COVID-19 is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If COVID-19 is still suspected based on exposure history together with other clinical findings, re-testing or testing with molecular methods should be considered by

healthcare providers in consultation with public health authorities.

Risks from a false negative result include: delay or lack of supportive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

A negative antigen test should not be the sole basis used to determine if a patient can end isolation precautions. For additional recommendations regarding infection control, refer to CDC's *Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare Settings* (Interim Guidance) (see links provided in "Where can I go for updates and more information" section).

## What is an EUA?

The United States (U.S.) FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19.

An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in diagnosing COVID-19.

The EUA for this test is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**

# FACT SHEET FOR HEALTHCARE PROVIDERS

Sofia 2 SARS Antigen FIA – Quidel Corporation

May 8, 2020

Coronavirus  
Disease 2019  
(COVID-19)

---

## Where can I go for updates and more information?

### **CDC webpages:**

**General:** <https://www.cdc.gov/COVID19>

**Healthcare Professionals:**

<https://www.cdc.gov/coronavirus/2019-nCoV/guidance-hcp.html>

**Information for Laboratories:** <https://www.cdc.gov/coronavirus/2019-nCoV/guidance-laboratories.html>

**Laboratory Biosafety:** <https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.html>

**Isolation Precautions in Healthcare Settings:**

<https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html>

**Specimen Collection:** <https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html>

**Infection Control:** <https://www.cdc.gov/coronavirus/2019-ncov/infection-control/index.html>

**Discontinuation of Isolation:** <https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html>

### **FDA webpages:**

**General:** [www.fda.gov/novelcoronavirus](http://www.fda.gov/novelcoronavirus)

**EUAs:** (includes links to patient fact sheet and manufacturer's instructions) <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>

### **Quidel Corporation:**

2005 East State Street Suite 100  
Athens, OH 45701 US

### **Technical Support:**

800.874.1517 (in the U.S.)  
858.552.1100 (outside the U.S.)  
technicalsupport@quidel.com

---

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**